Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

EPT Disclosure

8 Apr 2010 08:33

RNS Number : 8769J
Piper Jaffray Ltd
08 April 2010
 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

 

 

1. KEY INFORMATION

 

Name of exempt principal trader

Piper Jaffray Ltd.

Company dealt in

Ark Therapeutics Group plc 

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ord 1p

Date of dealing

07 April 2010

 

 

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

 

 

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

425,000 0.20%

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

425,000 0.20%

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

 

Class of relevant security:

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

 

(c) Rights to subscribe (Note 2)

 

Class of relevant security:

 

Details

 

 

3. DEALINGS (Note 3)

 

(a) Purchases and sales

 

Purchase/sale

 

Number of securities

Price per unit (Note 4)

Buy

1,992

9.53p

Buy

45,000

10.00p

Sell

7,188

10.25p

Buy

20,000

10.50p

 

 

(b) Derivatives transactions (other than options)

 

Product name,

e.g. CFD

Long/short (Note 5)

Number of securities (Note 6)

Price per unit (Note 4)

 

 

 

 

 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 6)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 4)

 

 

(ii) Exercising

 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 4)

 

 

 

 

(d) Other dealings (including new securities) (Note 3)

 

Nature of transaction (Note 7)

 

Details

Price per unit (if applicable) (Note 4)

 

 

 

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached? (Note 8) NO

 

 

Date of disclosure

08 April 2010

Contact name

Norman Gould

Telephone number

020 3142 8780

Name of offeree/offeror with which connected

Ark Therapeutics Group plc 

Nature of connection (Note 9)

Adviser and broker

 

 

Notes

 

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMUWOBRRAASRRR
Date   Source Headline
19th May 20087:00 amRNSResearch Update
16th May 20087:00 amRNSInterim Management Statement
24th Apr 20084:57 pmRNSAGM Results
22nd Apr 20087:00 amRNSRegulatory Update
17th Apr 20087:00 amRNSProduct Update
1st Apr 20083:26 pmRNSAnnual Information Update
31st Mar 200812:39 pmRNSTotal Voting Rights
28th Mar 20081:46 pmRNSRe Appointment
20th Mar 20087:00 amRNSBoard Appointment
11th Mar 20087:01 amRNSLaunch of Neuropad
11th Mar 20087:01 amRNSFinal Results
5th Mar 20085:20 pmRNSHolding(s) in Company
13th Feb 20087:00 amRNSManufacturing Update
31st Jan 200810:27 amRNSVoting Rights and Capital
23rd Jan 20084:56 pmRNSNotice of Results
18th Jan 20087:01 amRNSResearch Update
17th Jan 200810:42 amRNSRe: Employee Benefit Trust
11th Jan 200810:33 amRNSDirector/PDMR Shareholding
9th Jan 20084:50 pmRNSResignation of NED
8th Jan 20087:00 amRNSAcquisition
19th Dec 20074:37 pmRNSPrice Monitoring Extension
6th Dec 20075:48 pmRNSHolding(s) in Company
5th Dec 20071:39 pmRNSHolding(s) in Company
5th Dec 200712:41 pmRNSHolding(s) in Company
4th Dec 20075:40 pmRNSBlocklisting Interim Review
4th Dec 20074:56 pmRNSBlocklisting Interim Review
4th Dec 200711:50 amRNSHolding(s) in Company
30th Nov 200712:35 pmRNSDirector/PDMR Shareholding
30th Nov 200712:10 pmRNSVoting Rights and Capital
29th Nov 20072:17 pmRNSResult of EGM
28th Nov 20074:27 pmRNSRe: Placing and Open Offer
6th Nov 20077:01 amRNSPlacing and Open Offer
30th Oct 20075:08 pmRNSHolding(s) in Company
25th Oct 20077:01 amRNSResearch Update
22nd Oct 20071:01 pmRNSHolding(s) in Company
16th Oct 20073:23 pmRNSHolding(s) in Company
10th Oct 20077:01 amRNSRe Agreement
8th Oct 20077:00 amRNSRe Agreement
28th Sep 20073:06 pmRNSVoting Rights and Capital
31st Aug 200710:39 amRNSVoting Rights and Capital
29th Aug 20077:01 amRNSInterim Results
20th Aug 20077:02 amRNSRe: Product Launch
31st Jul 200711:23 amRNSVoting Rights and Capital
26th Jul 20077:01 amRNSResearch Update
24th Jul 200711:18 amRNSNotice of Results
23rd Jul 20077:01 amRNSRe: Cerepro
6th Jul 20077:00 amRNSEPO Grant Stroke Patent
29th Jun 20071:14 pmRNSVoting Rights and Capital
22nd Jun 20074:03 pmRNSHolding(s) in Company
15th Jun 20072:45 pmRNSDirector's Share Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.